MOREPEN LABORATORIES LIMITED Received a Patent for 3-AMINO-4-(2,4,5-TRIFLUOROPHENYL) BUTANOIC ACID IMPURITY IN SITAGLIPTIN PHOSPHATE — research and evidence
Record identification and provenance
The legacy article cites application 2300/DEL/2014 and grant 317954. A secondary patent listing describes an impurity-reduction process associated with Morepen, but a current official Indian register and prosecution record are required to confirm the complete chain, claim text and maintenance position. Similar drug-synthesis titles can refer to different filings. Verification focus: Match the exact application number, title, inventors, priority and patent number in the Patent Office record. Decision implication: The draft does not certify a current enforceable claim.
Why a process impurity matters
Pharmaceutical synthesis can generate structurally related impurities and residual reagents that require analytical control. The cited impurity concerns an amino-substituted trifluorophenyl butanoic-acid species in a sitagliptin-related process. The legal question is not merely whether an impurity is undesirable; it is whether a particular controllable process sequence was disclosed and claimed. Verification focus: Distinguish the impurity identity, analytical method and actual claimed process steps. Decision implication: Do not describe generic purification as a novel invention without a feature comparison.
Primary evidence starting point: IP India patent public search starting point. Where a source is a registry gateway, it establishes the verification route, not a verified finding on a named patent.
Process steps and measurable outcomes
A manufacturing claim may specify reagents, solvent system, reaction conditions, quenching, extraction, isolation or drying. Technical relevance can turn on sequence and ranges as much as chemical identity. Purity data must be traced to analytical protocols; a single statement of “high purity” is insufficient to assess reproducibility or claim scope. Verification focus: Extract the documented examples, impurity thresholds and HPLC or TLC test conditions. Decision implication: Process performance should be compared with a disclosed baseline, not inferred from product branding.
Prior chemistry and patent novelty
Searches should cover sitagliptin intermediates, reaction byproducts, crystallization, solvent extraction and earlier pharmaceutical process patents. Some earlier art may teach the impurity target without the same reduction steps, while other documents may disclose a very similar sequence with different naming. Identify the exact element combination. Verification focus: Make a claim-element chart against dated prior descriptions and scientific process literature. Decision implication: The strongest novelty analysis is chemical and chronological, not based on company reputation.
Section 3 and examination history
Indian pharmaceutical cases can raise statutory exclusions, including section 3(d) or 3(e), depending on the actual claim. Neither objection should be attributed to this Morepen file without a source. A process improvement can require a different legal analysis from a new form of a known drug. Verification focus: Obtain the first examination report and applicant amendments before reporting prosecution outcomes. Decision implication: Avoid asserting examiner findings or a legal rationale unsupported by primary records.
Present status and freedom to operate
A historic process patent can have a different status from composition patents covering sitagliptin or related intermediates. Maintenance, territorial scope, other family rights and third-party manufacturing patents must be examined independently. Even if a process is patented, another route may fall outside its claims; that requires a claim comparison, not an assumption. Verification focus: Reconcile the official current register and material third-party rights. Decision implication: A research overview does not authorize manufacture or determine infringement.
Complete process-intelligence dossier
A useful dossier lists verified identifiers, claims, flowchart, comparative tests, cited prior art, office action chronology and status findings. It should flag uncertain chemical synonyms and distinguish experimental statements from current regulatory compliance. The output can support manufacturing strategy, portfolio benchmarking or a later legal opinion. Verification focus: Maintain a traceable source note for each crucial process parameter and legal statement. Decision implication: No finished conclusion on this patent’s status is offered without the official file.
Worked research example (illustrative)
An illustrative process-comparison framework separates the impurity target from the method of achieving it. One process may lower a contaminant through selective extraction; another may change the precursor route to prevent its formation. Both may yield a similar final active ingredient but use materially different steps. For a Morepen-specific conclusion, the actual independent claim must identify which chemical intermediates, solvent conditions and operations are required. The draft deliberately does not fill these values from industry practice or treat third-party descriptions as the patent’s definitive operative wording.
Original evidence and comparison matrix
The proposed claim chart includes starting intermediate, reagent environment, reaction stage, quench, extraction, drying, impurity assay and quantitative outcome. A parallel prior-art chart identifies what each reference taught before the priority date. If a feature is missing from the patent specification, the analyst cannot cure the omission by adding typical commercial processing steps. If the claims are narrower than the broad process narrative, the chart should present that distinction prominently. Drug-manufacturing quality standards and patent claims also need separate review because compliance does not prove novelty.
Counterevidence, limits and next research decision
For legal status, the published article’s grant number and the available secondary process description provide leads but not a completed official file search. Current rights may differ after assignments, annuity lapses, revocation or amendments. The final source packet should therefore include an authenticated Indian patent extract, publication, complete specification, examination report and response history. Until those are obtained, the article should describe the technology analysis as a research method and retain open status findings. This avoids presenting an educational page as a manufacturing clearance opinion.
Research evidence-quality and publication controls
Evidence standard and reproducibility. Authenticate the Morepen filing and compare the process claim step by step with the reported impurity-control result. The primary documents should be identified by issuing institution, title or record number, and the date on which their contents were checked. Two apparently consistent secondary descriptions are not independent confirmation if they reproduce the same earlier article. Any comparison should use equivalent technical or legal units, and preserve adverse facts rather than selecting only supportive passages.
What would change this analysis? Secondary summaries may omit crucial ranges, while live legal status can change independently of historic publication. This possibility should be recorded in a dedicated contrary-evidence column, together with the source needed to investigate it. When a claim depends on an unverified record, it must remain an explicit research hypothesis.
Decision use. Keep chemical-process intelligence separate from a statement about current infringement or manufacturing authorization. Keep an audit trail connecting the source, the exact statement, the reader's decision and the remaining limitation. No generalized content strategy should obscure the independent user need of this protected URL.
Primary sources and verification boundaries
- IP India patent public search starting point
- Indian Patents Act, section 3, official source
- Morepen process document, third-party listing (not a current legal status source)
Source limitation: This article uses primary legal, patent, classification or platform materials where available. A primary-source gateway is not proof of any named patent’s current grant, title, claim scope or enforceability. The original WordPress article is retained in an editorial archive, not treated as authority for unverified legal claims.
General research information; not a legal opinion, patent validity opinion, regulatory clearance, or guarantee. Read the disclaimer
References and primary sources
- WIPO — PCT Frequently Asked Questions, updated August 2026. Official PCT procedure guidance.
- WIPO — PCT Applicant’s Guide, effective 23 April 2026. Official PCT applicant guide.
General research only. Any current grant, claim, ownership, legal status or professional opinion requires verification of official records and the facts of the particular matter. Full disclaimer


How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting